返回今日信号

NBIX

NMS 股策精挑入选日 2026-06-24 · 入选 4 天
Neurocrine Biosciences, Inc.
医疗保健 Drug Manufacturers - Specialty & Generic United States 官网
$168.52
+2.64% 当日
历史信号 6 次

AI选股记录

总览

这个股票来自自动 AI 选股池。以后只要 CLI 写入新的 ticker,这里会自动生成个股页面,不需要手工补页面。

2026-07-29 · 未来事件日历
NBIX
自动来源
记录数
1
最近更新
2026-06-26T14:17:47+00:00
该股票的历史 AI 入选记录
2026-07-29
总览
NBIX
-
查看AI历史

基本信息

市值
$16.94B
市盈率 TTM
25.93
前瞻市盈率
13.30
股息率
52周高点
$169.57
52周低点
$122.14
Beta
0.40
日均成交量
1.23M

成交结构

基于近 60 日量价数据观察资金强弱。

截至 2026-06-26
资金流强弱 MFI
60.7
偏多
Chaikin 资金流 CMF
+0.087
中性
量能变化
1.59x
放量
空头持仓比
7.37%
中等

交易信号历史

按时间回看该股票被模型捕捉到的买点信号。

共 6 条
2026-06-26
综合评分
可买入
评分
78
信号价
$164.18
当前
+2.6%
止损 $148.01 止盈 $196.53
2026-06-26
股策精挑
可买入
评分
74
信号价
$164.18
当前
+2.6%
止损 $151.05 止盈 $190.45
2026-06-25
综合评分
可买入
评分
78
信号价
$166.06
当前
+1.5%
止损 $149.45 止盈 $199.27
2026-06-25
股策精挑
可买入
评分
84
信号价
$166.06
当前
+1.5%
止损 $152.78 止盈 $192.63
2026-06-24
综合评分
可买入
评分
66
信号价
$161.44
当前
+4.4%
止损 $146.57 止盈 $191.19
2026-06-24
股策精挑
可买入
评分
72
信号价
$161.44
当前
+4.4%
止损 $148.52 止盈 $187.27

公司简介

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

员工数量 2,000 总部 San Diego, United States

最新资讯

外部数据 Yahoo Finance MarketWatch Stock Analysis Seeking Alpha